Cerus has announced a significant restructuring of its executive leadership, effective July 1, 2026. William Greenman will step down from his positions as President and Chief Executive Officer to transition into the role of Executive Chairman. This strategic shift in leadership was detailed in a recent regulatory filing submitted to the Securities and Exchange Commission.

The transition marks a change in the company's executive hierarchy while retaining Greenman's expertise within the organization. By moving to the Executive Chairman role, Greenman will continue to provide oversight and strategic guidance to the board and management team. The filing confirms the specific date of July 1, 2026, for these changes to take effect.

The announcement provides the necessary details regarding the personnel changes but does not specify the immediate successor for the President and CEO roles in the provided document. The move ensures continuity at the board level while facilitating a change in the company's operational leadership structure.

Cerus Corporation is set to showcase new evidence and global experience regarding its INTERCEPT Blood System at the 39th International ISBT Congress. The event is scheduled to take place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. The company's participation aims to highlight how blood centers utilize INTERCEPT technology to enhance blood safety, improve operational efficiency, and optimize patient care.

Christian Boutemy, vice president of international commercial operations at Cerus, emphasized the significance of the data being presented. He noted that the abstracts reflect a growing body of evidence supporting the INTERCEPT Blood System, alongside real-world experiences from blood centers across Asia. The presentations will feature innovations designed to optimize operations, such as reduced processing times using the LED-based INT200 illuminator and inventory management benefits linked to extended platelet shelf-life, as observed in Thailand.

A specific abstract from China will address persistent bacterial contamination risks in platelet components. This presentation reinforces the importance of a proactive pathogen-inactivation strategy in one of the world's largest transfusion markets. The full agenda includes a company-sponsored lunch symposium and various poster presentations detailing clinical and operational advancements.

Presentations and Abstracts

The following table outlines the key presentations and selected posters scheduled for the congress. All times are listed in Malaysian Time (MYT – UTC+8).

About Cerus Corporation

Cerus Corporation is dedicated to safeguarding the world's blood supply. Headquartered in Concord, California, the company develops and supplies technologies and pathogen-protected blood components to blood centers, hospitals, and patients. The INTERCEPT Blood System for platelets and plasma is available globally and holds both CE mark and FDA approval for these components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for producing Pathogen Reduced Cryoprecipitated Fibrinogen Complex, used to treat bleeding associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe and in late-stage clinical development in the U.S.